Executive Director of Cancer Therapeutics
Sean Buchanan, Ph.D.
Dr. Buchanan currently serves as the Executive Director of Cancer Therapeutics at the Genomics Institute of the Novartis Research Foundation (GNF), and is responsible for the application of the Institute’s cutting-edge drug discovery technologies to discover novel cancer medicines. Prior to joining GNF in 2020, Dr. Buchanan was at Eli Lilly where he contributed across the Oncology portfolio. He served as preclinical scientific lead for abemaciclib (Verzenio®), the translational science lead for multiple preclinical and clinical stage programs, and led both a Translational Biology group and a Ras drug discovery team. Prior to Eli Lilly he was at SGX Pharmaceuticals, a high-throughput X-Ray crystallography and structure-based drug design company, where he led the Cancer Biology group and several drug discovery initiatives, including programs targeting the c-Met kinase and Ras. Dr. Buchanan received his bachelor’s degree and Ph.D. in biochemistry from Cambridge University in the United Kingdom, and performed postdoctoral research in molecular genetics at UCSD.